Routine use of serial plasmatic CA 15-3 determinations during the follow-up of patients treated for breast cancer. Evaluation as factor of early diagnosis of recurrence;Utilisation en routine du CA 15.3 dans la surveillance des patientes traitées pour un cancer du sein invasif. Impact en termes de diagnostic précoce de récidive

Annales de Biologie Clinique

Volumn 66, Issue 4, 2008, Pages 385-392

  Chourin, S ^a   Veyret, C ^a   Chevrier, A ^a   Loeb, A ^a   Gray, C ^a   Basuyau, J ^a  

^a CENTRE HENRI BECQUEREL   (France)

Author keywords

Breast cancer; CA 15 3; Consensus; Follow up; Prognostic value

Indexed keywords

MUCIN 1;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; METASTASIS; MIDDLE AGED; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 51949087549     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2008.0244     Document Type: Article

References (27)

1. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUC-1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996 ; 56 : 4244-9.
2. Fung PY, Longenecker BM. Immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine adenocarcinoma (TA3-HA). Cancer Res 1991 ; 51 : 1170-6.
3. Ren J, Chen D, Li Y, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004 ; 5 : 107-8.
4. Green A, Liu YSV. Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast cancer tumor associated antigen 115D8/DF3. Proceedings of the American Association for Analytical Clinical Chemistry, Atlanta, 1985.
5. Hilkens J, Kroenzen V, Bonfrer JMG, Bruning PF. A sandwich radioimmunoassay for a new antigen (MAM-6) present in the sera of patient with metastasized carcinomas. In : Peeters H, ed. Protides of the biological fluids. Oxford : Pergamon press, 1984 : 651-3.
6. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984 ; 3 : 223-32.
7. ASCO (American Society of Clinical Oncology). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996 ; 14 : 2843-77.
8. e édition. Londres : John Libbey Eurotext, 2001.
9. ANAES. (Agence Nationale d'Accréditation et d'Evaluation en Santé). Marqueurs sériques dans les cancers du sein et les cancers colorectaux. Recommandations et Références médicales. ANAES. ANAES, 1997.
10. ANAES. Le cancer du sein : recommandations pour la pratique clinique. ANAES, 1998.
11. Molina R, Duffy MJ, Aronsson AC. Tumour markers in breast cancer. EGTM recommendations. Anticancer Res 1999 ; 19 : 2785-820.
12. ASCO. 2007 Update of Recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007 ; 25 : 1-26.
13. Basuyau JP, Blanc-Vincent MP, Bidart JM, et al. Standards, Options et Recommandations (SOR) : marqueurs tumoraux sériques du cancer du sein. Bull Cancer 2000 ; 87 : 723-37.
14. Bast RC, Ravdin P, Hayes DF, et al., American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 Update of recommendations for the use of tumors markers in breast and colorectal cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 ; 19 : 1865-78.
15. Molina R, Barak V, van Dalen A, et al. Tumour markers in breast cancer. EGTM recommendations 2005. European Group on Tumour Markers 2005. Tumor Biology 2005 ; 26 : 281-93.
16. Pestalozzi BC, Luporsi-Gely E, Jost LM, Bergh J. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2005 ; 16 (Suppl. 1) : i7-i9.
17. Kataja VV, Colleoni M, Bergh J. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2005 ; 16(Suppl 1) : i10-i12.
18. Kaplan E, Meier P. Non parametric estimation from incomplete estimations. J Am Stat Assoc 1958 ; 53 : 457-81.
19. Cox DR. Regression models and life tables (with discussion). J Royal Stat Sco 1972 ; B34 : 187-220.
20. Pecking AP, Mechelany-Corone C, Bertrand-Kermogant F, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Br Cancer 2001 ; 2 : 223-34.
21. Suarez M, Perez-Castejon MJ, Jimenez A. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002 ; 46 : 113-21.
22. Soletormos G, Schioler V, Nielsen D, Skovsgaard T, Dombernowski P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993 ; 39 : 2077-83.
23. Bonfrer JM. Working Group on Tumor Marker (WGTM). Tumor Biol 1990; 11 : 287-8.
24. Riedinger JM, Gauchez AS. Les marqueurs tumoraux circulants dans le cancer du sein : observations, recommandations, perspectives. Med Nucl 2002 ; 26 : 22-30.
25. Jäger W, Lang W. Erlangen tumor marker study on breast cancer. J Obstet Gynecol Reprod Biol 1993 ; 85 : 1-2.
26. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchick S. Treatment of disease-negative but mucin-like carcinoma associated antigen-positive breast cancer patients with tamoxifen : preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 1994 ; 35 : 80-3.
27. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by "early" salvage treatment of breast cancer patients : a retrospective 6-year study. Br J Cancer 1997 ; 76 : 1106-11.